China Chemical Pharmaceutical Industry Report, 2009-2010
  • Dec/2010
  • Hard Copy
  • USD $2,300
  • Pages:115
  • Single User License
    (PDF Unprintable)       
  • USD $2,200
  • Code: ZYM017
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $3,300
  • Hard Copy + Single User License
  • USD $2,500
      
China’s chemical pharmaceutical industry has maintained a good momentum of growth in recent years. In 2009, the number of chemical pharmaceutical manufacturers reached 2,434, up 7.5% year-on-year; the total value of industrial output achieved RMB420.7 billion, rising 10.9% year-on-year; and the pharmaceutical operating income reached RMB424.3 billion, a year-on-year increase of 19.5%.

Regarding the product structure, China is a big producer of active pharmaceutical ingredients (API). As of August 2010, China had had 1,197 active pharmaceutical ingredient manufacturers, been capable of producing over 1,500 categories of active pharmaceutical ingredients, and ranked No.1 in the world in terms of the output of penicillin, vitamins and antipyretics & analgesics. Furthermore, China is also the world’s biggest exporter of active pharmaceutical ingredients, with the export volume approximating half of the domestic output of active ingredients. From the perspective of export value, active pharmaceutical ingredient accounted for 80% of China’s total pharmaceutical export value in 2009; finished dosage form mainly addresses domestic demand, and only covered 6% of China’s total pharmaceutical export value in 2009.

China’s Pharmaceutical Export by Value, 2009
 2010120707.gif
Source: General Administration of Customs, ResearchInChina

China has many chemical pharmaceutical manufacturers, and the whole industry features a low concentration rate in general. However, the segmented markets have a higher concentration rate affected by technology, raw materials source, policy and large R&D investment of chemical pharmaceutical industry. For example, China Pharmaceutical Group Limited, Shandong Luwei Pharmaceutical Co., Ltd., Northeast Pharmaceutical Group Co., Ltd. and North China Pharmaceutical Group Corp. totally held over 90% shares in the domestic vitamin market, while Zhejiang Medicine Co., Ltd. alone covered 50% shares of the global vitamin H market in 2009.

Based on the abundant statistics, the report not only underlines the overall operation including the current development, profitability, import & export and competitive layout of China’s chemical pharmaceutical industry and its sub-sectors, but also makes an in-depth analysis of the operation and development advantages of China’s ten leading active pharmaceutical ingredient manufacturers and ten finished dosage form companies.

Northeast Pharmaceutical Group Co., Ltd., Zhejiang Medicine Co., Ltd. and Zhejiang NHU Co., Ltd. are China’s major vitamin manufacturers, as well as the key vitamin suppliers in the world. In the meantime, they are also actively expanding to produce other categories of active pharmaceutical ingredients.

North China Pharmaceutical Group Corp (NCPC) and Shandong Xinhua Pharmaceutical Company Limited (Xinhua Pharm) are China’s important antibiotic production bases. NCPC tops in China in terms of penicillin capacity and output, but is transferring to cephalosporin antibiotics under the mounting pressure of overcapacity; Xinhua Pharm is the biggest antipyretics and analgesics producer and exporter in Asia.

Zhejiang Hisun Pharmaceutical Co., Ltd. (Hisun Pharma) and Zhejiang Huahai Pharmaceutical Co., Ltd. (Huahai Pharma) are the most competitive producers of special active pharmaceutical ingredients in China, both specializing in the R&D and production of chemical pharmaceuticals in the fields like anti-cancer, cardiovascular and nerve center. Moreover, the two companies both maintain a close cooperation with foreign pharmaceutical giants. Hisun Pharma cooperates with Eli Lilly and Schering-Plough in R&D and outsourcing, while Huahai Pharma supplies special active pharmaceutical ingredients and manufactures some finished dosage forms for German Boehringer Ingelheim GmbH and Swiss NOVARTIS.

Shenzhen Hepalink Pharmaceutical Co., Ltd is the world’s largest producer and seller as well as China’s only U.S. FDA and EU CEP– certified producer of heparin sodium active pharmaceutical ingredients. It occupied 26.7% of the worldwide sales volume of heparin sodium of 23.6 trillion units in 2009. Tianjin Tianyao Pharmaceutical Co., Ltd. and Zhejiang Xianju Pharmaceutical Co., Ltd. are the world’s major cortical hormone active pharmaceutical ingredients suppliers, monopolizing the mainland Chinese dexamethasone market in the ratio of 7:3.
1. Overview of Chemical Pharmaceutical Industry 
1.1 Definition & Classification  
1.2 Industry Chain 

2. Development of Global Chemical Pharmaceutical Industry 
2.1 Status Quo  
2. 2 Market Supply & Demand 
2.2.1 Product Structure 
2.2.2 Regional Structure 
2.3 Major Countries and Regions 
2.3.1 North America 
2.3.2 Europe 
2.3.3 Japan 
2.4 Development Trend 

3. Development of China’s Chemical Pharmaceutical Industry 
3.1 Status Quo 
3.2 Profitability 
3.2.1 Active Pharmaceutical Ingredient
3.2.2 Finished Dosage Form
3.3 Import & Export
3.3.1 Active Pharmaceutical Ingredient
3.3.2 Finished Dosage Form
3.4 Competition Layout
3.5 Development Trend

4. China’s Chemical Pharmaceutical Market Segments
4.1 Vitamins 
4.1.1 Status Quo
4.1.2 Competition Layout
4.1.3 Import & Export
4.2 Antibiotics 
4.2.1 Status Quo
4.2.2 Competition Layout
4.2.3 Import & Export
4.3 Antipyretics and Analgesics 
4.3.1 Status Quo
4.3.2 Competition Layout
4.3.3 Import & Export
4.4 Hormones 
4.4.1 Status Quo
4.4.2 Competition Layout
4.4.3 Import & Export
4.5 Anti-tumor 
4.5.1 Status Quo
4.5.2 Competition Layout
4.6 Cardiovascular and Cerebrovascular
4.6.1 Status Quo
4.6.2 Competition Layout

5. Domestic Manufacturers of Active Pharmaceutical Ingredients 
5.1 Northeast Pharmaceutical Group Co., Ltd 
5.1.1 Profile
5.1.2 Operation
5.1.3 Development Trend & Advantages
5.2 North China Pharmaceutical Group Corp(NCPC) 
5.2.1 Profile
5.2.2 Operation
5.3 Zhejiang Medicine Co., Ltd 
5.3.1 Profile
5.3.2 Operation
5.3.3 Development Trend & Advantages
5.4 Zhejiang Hisun Pharmaceutical Co., Ltd 
5.4.1 Profile
5.4.2 Operation
5.4.3 Development Trend & Advantages
5.5 Zhejiang NHU Company Ltd 
5.5.1 Profile
5.5.2 Operation
5.5.3 Development Trend & Advantages
5.6 Shandong Xinhua Pharmaceutical Company Limited 
5.6.1 Profile
5.6.2 Operation
5.6.3 Development Trend & Advantages
5.7 Shenzhen Hepalink Pharmaceutical Co., Ltd 
5.7.1 Profile
5.7.2 Operation
5.7.3 Development Trend & Advantages
5.8 Zhejiang Xianju Pharmaceutical Co., Ltd 
5.8.1 Profile
5.8.2 Operation
5.8.3 Development Trend& Advantages 
5.9 Zhejiang Huahai Pharmaceutical Co., Ltd 
5.9.1 Profile
5.9.2 Operation
5.9.3 Development Trend & Advantages
5.10 Tianjin Tianyao Pharmaceutical Co., Ltd 
5.10.1 Profile
5.10.2 Operation
5.10.3 Development Trend & Advantages

6. Domestic Manufacturers of Finished Dosage Form  
6.1 Beijing Double-Crane Pharmaceutical Co., Ltd 
6.1.1 Profile
6.1.2 Operation
6.1.3 Development Trend
6.2 Jiangsu Hengrui Medicine Co., Ltd 
6.2.1 Profile
6.2.2 Operation
6.2.3 Development Trend
6.3 Harbin Pharm. Group Sanjing Pharmaceutical Co., Ltd 
6.3.1 Profile
6.3.2 Operation
6.3.3 Development Trend
6.4 Guangzhou Baiyunshan Pharmaceutical Co., Ltd
6.4.1Profile
6.4.2 Operation
6.4.3 Development Trend
6.5 Livzon Pharmaceutical Group Inc. 
6.5.1 Profile
6.5.2 Operation
6.5.3 Development Trend
6.6 Shanghai Fosun Pharmaceutical (Group) Co., Ltd 
6.6.1 Profile
6.6.2 Operation
6.6.3 Development Trend
6.7 Chongqing Huapont Pharm. Co., Ltd 
6.7.1 Profile
6.7.2 Operation
6.7.3 Development Trend
6.8 Hainan Haiyao Co., Ltd 
6.8.1 Profile
6.8.2 Operation
6.8.3 Development Trend
6.9 Jiangsu Nhwa Pharmaceutical Co., Ltd 
6.9.1 Profile
6.9.2 Operation
6.9.3 Development Trend
6.10 Huadong Medicine Co., Ltd 
6.10.1 Profile
6.10.2 Operation
6.10.3 Development Trend
China’s Chemical Pharmaceutical Industry Segments
Chemical Pharmaceutical Industry Value-added Chain
Global Pharmaceutical Sales Revenue and Growth Rate, 2002-2009
New Medicine Launched Worldwide, 2000-2009
Closed M&A Cases and Transaction Value in Global Pharmaceutical Industry, 2004-H12009
Global Generic Medicines (by Sales Revenue), 2003-2009
Sales Revenue of Blockbuster Chemical Pharmaceutical Products in the World, 2009
Global Medicine Sales Revenue (by Region), 2009
Global Generic Medicine Sales Revenue (by Region), 2009
Proportion of Health Care Spending to GDP in USA and Canada, 1970-2007
Sales Revenue and Growth Rate of Medicine in North America, 2007-2009
Proportion of Generic Medicine in the U.S. Pharmaceutical Market by Sales Volume and Revenue, 2000-2008
Proportion of Health Care Spending to GDP in Germany and UK, 1970-2007
Sales Revenue and Growth Rate of Medicine in Europe, 2007-2009  
Proportion of Health Care Spending to GDP in Japan, 1970-2007
Sales Revenue and Growth Rate of Medicine in Japan, 2007-2009  
Average Annual Growth Rate of Global Pharmaceutical Market by Region, 2010-2014
Number of Chemical Pharmaceutical Enterprises in China, 2006-May 2010
Industrial Output Value and Sales Revenue of China’s Chemical Pharmaceutical Industry, 2006-2009
Proportion of Chemical Pharmaceutical Industrial Output Value to GDP in China, 2005-2009
Output of API in China, 2006-Aug 2010
Industrial Output Value of API And Finished Dosage Form in China, 2006-2009
Prime Operating Revenue and Total Profit of China’s API Industry, 2006-May 2010
Gross Margin and Sales Profit Margin of China’s API Industry, 2006-May 2010
Prime Operating Revenue and Total Profit of China’s Finished Dosage Form Industry, 2006-May 2010
Gross Margin and Sales Profit Margin of China’s Finished Dosage Form Industry, 2006-May 2010
China’s Export of Medicine (By Value), 2009
API Export, 2009
Top 10 Pharmaceutical Enterprises in China by Export, 2009
Monthly Export Volume and Value of Chemical Medicine in Unmeasured Dose in China, 2009
Overseas Market Distribution of Chemical Medicine in Unmeasured Dose in China(by Value), 2009  
Monthly Export Volume and Value of Chemical Medicine in Measured Dose in China, 2009 
Overseas Market Distribution of Chemical Medicine in Measured Dose in China(by Value), 2009
Monthly Import Volume and Value of Chemical Medicine in Unmeasured Dose in China, 2009
Importing Countries of Chemical Medicine in Unmeasured Dose in China (by Value), 2009
Monthly Import Volume and Value of Chemical Medicine in Measured Dose in China, 2009
Importing Countries of Chemical Medicine in Measured Dose in China (by Value), 2009
Segment Market Shares of Medicine Procured by Chinese Hospitals, 2009 (by Usage)
China’s Health Care Expenditure and Proportion of Health Care Expenditure to GDP, 2000-2009
Structure and Proportion of Health Care Expenditure in China, 2000-2008
Proportion of Health Care Expenditure to Total Consumption Expenditure of Urban and Rural Residents in China, 2005-2008
Major Chemical Pharmaceutical Projects under Planning/Construction in China, 2009
Population and Proportion of People Aged over 65 in China, 2001-2009
Market Prices of Main Vitamin APIs in China, 2006-Sep 2010
Major Vitamin Manufacturers and Capacity in China, 2009
Export Volume and Value of Vitamin in China, Jan-Sep 2010  
Import Volume and Value of Vitamin in China, Jan-Sep 2010 
Output of Main Antibiotic API Products in China, 2009
Output of Major Antibiotic Finished Dosage Form Products in China, 2009
Major Antibiotic API Manufacturers and Capacity in China, 2009
Import Volume and Value of Antibiotic API and Finished Dosage Form in China, 2006-Aug 2010
Antibiotic API Export Volume and Value in China, 2006-Aug 2010
Import & Export Volume and Value of Paracetamol in China, Jan-Sep 2010
Import & Export Volume and Value of Dipyrone in China, Jan-Sep 2010
Import & Export Volume and Value of Aspirin in China, Jan-Sep 2010
Import & Export Volume and Value of Caffeine in China, Jan-Sep 2010
Import & Export Volume and Value of Ibuprofen in China, Jan-Sep 2010
Export Volume and Value of Major Steroid Hormone Products in China, 2009
Global Antineoplastic Medicine Market Scale, 2003-2008
Market shares of Major Antineoplastic Companies in China, 2007
Prices of Cardiovascular Medicine Purchased by Chinese Hospitals,2005-2009
Western Cardiovascular Medicine (by Usage) in China, 2005-2009
Market Shares of Western Cardiovascular and Cerebrovascular Medicine (by Enterprise) in China, 2007-2009
Price and Proportion of Western Cardiovascular and Cerebrovascular Medicine (by Chemical Structure) Purchased by Chinese Hospitals, 2009
Operating Revenue of North China Pharmaceutical (by Industry and Product), 2009         
Operating Revenue of Northeast Pharmaceutical (by Industry and Product), H1 2010        
Operating Revenue of North China Pharmaceutical (by Region), 2009  
Operating Revenue of Northeast Pharmaceutical (by Region), H1 2010    
Top 5 Clients of Northeast Pharmaceutical by Operating Revenue, 2009
Operating Revenue of North China Pharmaceutical (by Industry and Product), 2009        
Operating Revenue of North China Pharmaceutical (by Industry and Product), H1 2010
Operating Revenue of North China Pharmaceutical (by Region), 2009
Operating Revenue of North China Pharmaceutical (by Region), H1 2010
Top 5 Clients of North China Pharmaceutical by Operating Revenue, 2009
Top 5 Clients of North China Pharmaceutical by Operating Revenue, H1 2010
Operating Revenue of Zhejiang Medicine (by Industry and Product), 2009
Operating Revenue of Zhejiang Medicine (by Industry and Product), H1 2010
Operating Revenue of Zhejiang Medicine (by Region), 2009    
Operating Revenue of Zhejiang Medicine (by Region), H1 2010    
Prime Operating Revenue and Total Profit of Hisun, 2007-H1 2010      
Operating Profit Margin of Hisun, 2007-H1 2010
Operating Revenue and Proportion of Self-made Medicine of Hisun, 2007-H1 2010
Operating Revenue of API and Finished Dosage Form of Hisun, 2007-2009
Operating Revenue of Hisun (by Region), 2007-H1 2010     
DMF and COS Certification of Hisun, June 2010 
Operating Revenue of Hisun (by Product), 2007-H1 2010
Hisun’s R&D Investment and Contribution to Sales Revenue of Parent Company, 2007-2009 
Operating Revenue of NHU (by Industry and Product), 2009   
Operating Revenue of NHU (by Industry and Product), H1 2010      
Operating Revenue of NHU (by Region), 2009      
Operating Revenue of NHU (by Region), H1 2010    
Top 5 Clients of NHU by Operating Revenue, 2009        
Top 5 Clients of NHU by Operating Revenue, H1 2010
Operating Revenue of Xinhua Pharmaceutical (by Product), 2009     
Operating Revenue of Xinhua Pharmaceutical (by Product), 2010       
Top 5 Clients of Xinhua Pharmaceutical by Operating Revenue, 2009
Top 5 Clients of Xinhua Pharmaceutical by Operating Revenue, H1 2010
Domestic Market Shares of Main Products of Xinhua Pharmaceutical, 2009
Operating Revenue and Net Profit of Hepalink, 2007-H1 2010
Prime Operating Revenue of Hepalink (by Product), 2007- H1 2010     
Gross Margin of Hepalink (by Product), 2007-H1 2010
Top 5 Clients of Hepalink by Sales Revenue, 2009-H1 2010
Export Volume, Value and Average Prices of Major Heparin Enterprises in China, Jan-Sep 2009
Hepalink’s Shares in Chinese and Global Markets, 2007-2009
Global Demand for Heparin API and Global Supply of Hepalink, 2009
Operating Revenue of Xianju Pharma (by Product), 2009       
Operating Revenue of Xianju Pharma (by Product), H1 2010       
Operating Revenue of Xianju Pharma (by Region), 2009
Operating Revenue of Xianju Pharma (by Region), H1 2010  
Eleven Subsidiaries of Huahai Pharmaceuticals 
Prime Operating Revenue and Total Profit of Huahai Pharmaceuticals, 2007-H1 2010
Prime Operating Revenue of Huahai Pharmaceuticals (by Product), 2007-H1 2010    
DMF and COS Certification of Huahai Pharmaceuticals, by Jun 2010
Prime Operating Revenue of Huahai Pharmaceuticals (by Region), 2007-H1 2010
Top 5 Clients of Huahai Pharmaceuticals by Operating Revenue, 2009
Ten Billion / Year Export Finished Dosage Form Project of Huahai Pharmaceuticals 
API Output and Growth Rate of Tianyao Pharmaceutical, 2007-2009
Operating Revenue of Tianyao Pharmaceutical (by Product), 2009
Operating Revenue of Tianyao Pharmaceutical (by Product), H1 2010
Operating Revenue of Tianyao Pharmaceutical (by Region), 2009    
Operating Revenue of Tianyao Pharmaceutical (by Region), H1 2010    
Prime Operating Revenue of Double-Crane Pharmaceutical (by Industry and Product), 2009          
Prime Operating Revenue of Double-Crane Pharmaceutical (by Industry and Product), H1 2010         
Prime Operating Revenue of Double-Crane Pharmaceutical (by Region), 2009
Prime Operating Revenue of Double-Crane Pharmaceutical (by Region), H1 2010
Operating Revenue of Jiangsu Hengrui Medicine (by Product), 2009 
Operating Revenue of Jiangsu Hengrui Medicine (by Product), H1 2010
Operating Revenue of Jiangsu Hengrui Medicine (by Region), 2009  
Operating Revenue of Jiangsu Hengrui Medicine (by Region), H1 2010  
Operating Revenue of Sanjing Pharmaceutical (by Product), 2009        
Operating Revenue of Sanjing Pharmaceutical (by Product), H1 2010
Operating Revenue of Sanjing Pharmaceutical (by Region), 2009      
Operating Revenue of Sanjing Pharmaceutical (by Region), H1 2010     
Operating Revenue of Baiyunshan Pharmaceutical (by Industry and Product), 2009          
Operating Revenue of Baiyunshan Pharmaceutical (by Industry and Product), H1 2010      
Operating Revenue of Baiyunshan Pharmaceutical (by Region), 2009     
Operating Revenue of Baiyunshan Pharmaceutical (by Region), H1 2010
Operating Revenue of Livzon Pharmaceutical Group (by Industry), 2009
Operating Revenue of Livzon Pharmaceutical Group (by Industry), H1 2010
Operating Revenue of Livzon Pharmaceutical Group (by Region), 2009   
Operating Revenue of Livzon Pharmaceutical Group (by Region), 2010 
Operating Revenue of Fosun Pharmaceutical (by Product), 2008-H1 2010
Operating Revenue and Operating Profit of Western Medicine of Fosun Pharmaceutical, 2008-H1 2010
Operating Revenue of Huapont Pharm. (by Industry, Product and Region), 2009      
Operating Revenue of Huapont Pharm. (by Industry and Product), H1 2010
Operating Revenue of Hainan Haiyao (by Industry and Product), 2009        
Operating Revenue of Hainan Haiyao (by Industry and Product), H1 2010
Operating Revenue of Hainan Haiyao (by Region), 2009
Operating Revenue of Hainan Haiyao (by Region), H1 2010
Operating Revenue of Nhwa Pharmaceutical (by Industry and Product), 2009 
Operating Revenue of Nhwa Pharmaceutical (by Industry and Product), H1 2010
Operating Revenue of API and Finished Dosage Form of Nhwa Pharmaceutical (by Region), 2009    
Operating Revenue of API and Finished Dosage Form of Nhwa Pharmaceutical (by Region), H1 2010      
Operating Revenue of Huadong Medicine (by Industry and Product), 2009          
Operating Revenue of Huadong Medicine (by Industry and Product), H1 2010          
Operating Revenue of Huadong Medicine (by Region), 2009
Operating Revenue of Huadong Medicine (by Region), H1 2010      

China Vitamin Industry Report,2014-2017

China is the world's largest production base of vitamins, with vitamin C and vitamin E as its most important products, wherein vitamin C and related products account for more than 60% of its total out...

China Chemical Pharmaceutical Industry Report, 2013-2016

Chemical pharmaceutical consists mainly of chemical drug preparation and active pharmaceutical ingredient (API), and the gross margin of chemical drug preparation industry is generally higher than tha...

China Pharmaceutical Distribution Industry Report, 2013

Thanks to the continuous advancement in new medical reform, China’s pharmaceutical distribution industry has maintained a fairly rapid growth in recent years, with the sales value showed a CAGR of rou...

China Pharmaceutical Glass Packaging Industry Report, 2013-2016

Influenced by the substitution of plastic, aluminum foil and other new packaging materials as well as the declining packaging material purchase prices incurred by the medical reform, China pharmaceuti...

China Chinese Patent Medicine Industry Report, 2013-2016

Chinese patent medicine refers to the certain dosage forms of medicine, under the guidance of TCM (traditional Chinese medicine) theory, made from traditional Chinese medicinal materials in accordance...

Global and China Monoclonal Antibody Industry Report, 2013-2017

Currently, monoclonal antibody agents have been successfully used in the treatment of tumors, cancers and other serious diseases as a heavyweight in the biopharmaceutical industry. In 2009-2012, the m...

Global and China Insulin Industry Report, 2013-2017

As the third largest human health disease following neoplastic disease, cardiovascular and cerebrovascular diseases, the number of diabetic patients has continued growing from 246 million in 2007 to 3...

China Large Volume Parenteral (LVP) Industry Report, 2013-2015

Under the context of China's medical reform and sustainable development of the pharmaceutical market, the output and demand of Large Volume Parenteral (LVP) which is one of the top five Chinese prepar...

China Independent Clinical Laboratory Industry Report,2013-2015

Restricted by the health care system and the medical inspection level (Chinese firms mainly lag behind foreign counterparts in molecular diagnostics and other special tests), Chinese independent clini...

China Vitamin Industry Report, 2012-2015

As a great power of vitamin production and export, China has long been known as the world’s vitamin production base. In recent years, its vitamin exports on external demand accounted for about 80% of ...

China Pharmaceutical Equipment Industry Report, 2012-2015

Driven by the new GMP certification as well as the brisk downstream demand, China pharmaceutical equipment industry has seen steady progress in sales volume and technological content of products over ...

China Genetic Engineering Drug Industry Report, 2011-2012

China gets a late start in developing genetic engineering drug industry, but has achieved leapfrog advance. At present, China has at least one hundred enterprises involved in genetic engineering drugs...

China Animal Vaccine Industry Report, 2011-2012

Along with the frequent outbreaks of animal epidemics, the government’s increasing investment in epidemic prevention and the implementation of compulsory immunization system, Chinese animal vaccine ma...

China Human Vaccine Industry Report, 2011-2012

After decades of development, China has become one of the major producer and consumers of human vaccine around the world. In 2011, human vaccine manufacturers numbered 38 in China and the lot release ...

China Chemical Pharmaceutical Industry Report, 2011

In Jan.-Aug., 2011, the gross industrial output value of Chinese chemical pharmaceutical industry surged by 24.54% YoY to RMB460.531 billion, up 2.67 percentage points over the same period of last yea...

China Pharmaceutical Equipment Industry Report, 2011-2012

In recent years, Chinese pharmaceutical equipment industry has witnessed significant growth in both product quality and technological content, as well as steady rise of sales volume. According to Chin...

China Animal Vaccine Industry Report, 2010-2011

China animal vaccine industry has been fast-growing. The market maintained an average annual growth rate up to 13.6% in 2006-2010, and reached around RMB 7.5 billion in 2010, up 21.0% YoY. With the in...

China Human Vaccine Industry Report, 2010-2011

With the improvement of economy and people’s disease prevention awareness, China’s human vaccine market has expanded in recent years, growing at a CAGR of 24.0% in 2007-2010. In particular, the market...

2005-2014 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号
在线客服系统